Clinical parameters of patients with PTCL-NOS and their distribution according to ENO1 and TPI1 expression by IHC
| Clinical feature . | ENO1 “low” (n = 37) . | ENO1 “high” (n = 36) . | P . | TPI1 “low” (n = 38) . | TPI1 “high” (n = 39) . | P . |
|---|---|---|---|---|---|---|
| Age, y | .34 | .27 | ||||
| Median | 58 | 63 | 56 | 62 | ||
| Range | 20-92 | 25-82 | 20-92 | 20-92 | ||
| Sex | .16 | 1.00 | ||||
| Female | 20 | 13 | 18 | 18 | ||
| Male | 17 | 23 | 20 | 21 | ||
| Performance status | .41 | .71 | ||||
| 0-1 | 30 | 25 | 35 | 33 | ||
| 2-4 | 7 | 10 | 3 | 5 | ||
| Missing | 0 | 1 | 0 | 1 | ||
| Elevated LDH | .09 | .15 | ||||
| Yes | 17 | 24 | 19 | 25 | ||
| No | 18 | 10 | 18 | 11 | ||
| Missing | 2 | 2 | 1 | 3 | ||
| Stage (Ann Arbor) | .61 | .39 | ||||
| I-II | 8 | 9 | 7 | 11 | ||
| III-IV | 27 | 23 | 29 | 24 | ||
| Missing | 2 | 4 | 2 | 4 | ||
| Extranodal sites | .56 | 1.00 | ||||
| ≤1 | 30 | 26 | 30 | 30 | ||
| >1 | 15 | 5 | 8 | 9 | ||
| Missing | 2 | 5 | 0 | 0 | ||
| IPI | .53 | .92 | ||||
| Low | 10 | 6 | 10 | 7 | ||
| Low-intermediate | 11 | 6 | 10 | 8 | ||
| High-intermediate | 7 | 8 | 8 | 9 | ||
| High | 4 | 6 | 5 | 5 | ||
| Missing | 5 | 10 | 5 | 10 | ||
| Treatment (first line) | 1.00 | 1.00 | ||||
| Curative intent* | 34 | 34 | 36 | 36 | ||
| Other† | 3 | 2 | 2 | 3 | ||
| Consolidation with HDT/ASCT | .52 | 1.00 | ||||
| Yes | 4 | 6 | 5 | 6 | ||
| No | 33 | 30 | 33 | 33 | ||
| Outcome | .01 | .57 | ||||
| 5-y OS, % | 43 | 15 | 38 | 20 | ||
| 95% CI | 27-58 | 5-30 | 23-53 | 10-35 |
| Clinical feature . | ENO1 “low” (n = 37) . | ENO1 “high” (n = 36) . | P . | TPI1 “low” (n = 38) . | TPI1 “high” (n = 39) . | P . |
|---|---|---|---|---|---|---|
| Age, y | .34 | .27 | ||||
| Median | 58 | 63 | 56 | 62 | ||
| Range | 20-92 | 25-82 | 20-92 | 20-92 | ||
| Sex | .16 | 1.00 | ||||
| Female | 20 | 13 | 18 | 18 | ||
| Male | 17 | 23 | 20 | 21 | ||
| Performance status | .41 | .71 | ||||
| 0-1 | 30 | 25 | 35 | 33 | ||
| 2-4 | 7 | 10 | 3 | 5 | ||
| Missing | 0 | 1 | 0 | 1 | ||
| Elevated LDH | .09 | .15 | ||||
| Yes | 17 | 24 | 19 | 25 | ||
| No | 18 | 10 | 18 | 11 | ||
| Missing | 2 | 2 | 1 | 3 | ||
| Stage (Ann Arbor) | .61 | .39 | ||||
| I-II | 8 | 9 | 7 | 11 | ||
| III-IV | 27 | 23 | 29 | 24 | ||
| Missing | 2 | 4 | 2 | 4 | ||
| Extranodal sites | .56 | 1.00 | ||||
| ≤1 | 30 | 26 | 30 | 30 | ||
| >1 | 15 | 5 | 8 | 9 | ||
| Missing | 2 | 5 | 0 | 0 | ||
| IPI | .53 | .92 | ||||
| Low | 10 | 6 | 10 | 7 | ||
| Low-intermediate | 11 | 6 | 10 | 8 | ||
| High-intermediate | 7 | 8 | 8 | 9 | ||
| High | 4 | 6 | 5 | 5 | ||
| Missing | 5 | 10 | 5 | 10 | ||
| Treatment (first line) | 1.00 | 1.00 | ||||
| Curative intent* | 34 | 34 | 36 | 36 | ||
| Other† | 3 | 2 | 2 | 3 | ||
| Consolidation with HDT/ASCT | .52 | 1.00 | ||||
| Yes | 4 | 6 | 5 | 6 | ||
| No | 33 | 30 | 33 | 33 | ||
| Outcome | .01 | .57 | ||||
| 5-y OS, % | 43 | 15 | 38 | 20 | ||
| 95% CI | 27-58 | 5-30 | 23-53 | 10-35 |
ASCT, autologous stem cell transplantation; CHOP, cyclophosphamide, hydrocydaurubicin, vincristine, prednisone; HDT, high-dose therapy; IPI, International Prognostic Index; LDH, lactate dehydrogenase.
CHOP/CHOP-like and/or radiotherapy in low-stage disease.
Palliative treatment or unspecified treatment.